Skip to content

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

Primary Hyperoxaluria Type 1

The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    0 and up

Participation Criteria

Inclusion Criteria:

* Documented diagnosis of PH1, per physician's determination

Exclusion Criteria:

* Currently enrolled in a clinical trial for any investigational agent

Study Location

Clinical Trial Site
Clinical Trial Site
Toronto, Ontario
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Hamilton, Ontario
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Laurier, Quebec
Canada

Contact Study Team

Study Sponsored By
Alnylam Pharmaceuticals
Participants Required
More Information
Study ID: NCT04982393